EUCTR2014-002285-76-DK
Active, not recruiting
Phase 1
The Effects of Liraglutide in Patients With Insulin Pump Treated Type 1 Diabetes: A Randomized, Placebo-Controlled Trial. The Lira Pump Trial. - The Lira Pump Trial.
DrugsVictoza
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hvidovre University Hospital
- Enrollment
- 44
- Status
- Active, not recruiting
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\-Age 18 – 70 years
- •\-T1D \= 1 years
- •\-BMI \> 25 kg/m2
- •\-HbA1c \= 58 mmol/mol (7\.5%)
- •\-CSII use \= 1 year
- •\-Use of carbohydrate counting and the insulin pump bolus calculator
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 44
Exclusion Criteria
- •\-Gastroparesis
- •\-Impaired renal function (eGFR \< 60 ml/min/1\.73m2\)
- •\-Liver disease with ALAT \> 2\.5 times the upper limit of the reference interval
- •\-Acute or chronic pancreatitis or history of chronic pancreatitis or idiopathic acute pancreatitis
- •\-Inflammatory bowel disease
- •\-History of cancer (except basal cell skin cancer) which in the investigators opinion could interfere with the results of the trial, or cancer during the past 5 years
- •\-Thyroid adenoma
- •\-Subjects with personal or family history of MTC or MEN2
- •\-Use of anti\-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start
- •\-Known or suspected alcohol or drug abuse
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Efficacy of liraglutide in non-insulin-dependent diabetic patients with GAD autoantibody -positiveDiabetesJPRN-UMIN000010043niversity of Yamanashi, Faculty of Medicine Department of Internal Medicine III60
Completed
Not Applicable
Effects of liraglutide add-on to insulin therapy in patients with type 2 diabetesJPRN-UMIN000030622Yokohama City University80
Active, not recruiting
Phase 1
The effect of a new anti-diabetic drug (Liraglutide) on body weight in patients with type 2 diabetes mellituspatients with type 2 diabetes mellitusMedDRA version: 14.0Level: PTClassification code 10053247Term: Insulin-requiring type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2011-000411-12-NLMC St Radboud80
Terminated
Phase 4
ovel approaches to manage glucocorticoid-induced diabetes in hospital inpatientsglucocorticoid-induced or -exacerbated diabetesMetabolic and Endocrine - DiabetesACTRN12615000333516Alfred Hospital30
Active, not recruiting
Not Applicable
Assessing the efficacy and safety of the GLP1-agonist liraglutide in patients who developed diabetes as a consequence of the use of anti-psychotic drugsEUCTR2013-005395-18-NLniversity Medical Center Utrecht